Rosario D. M.
- Country
- Italy
- Department
- N/A
Research Overview
- Evaluation of the Efficacy, Safety, and Tolerability of Subcutaneous REGN7999 in Adults with Iron Overload Due to Non-Transfusion Dependent Beta-Thalassemia
- A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Anumigilimab in Adults with Sickle Cell Disease
- Efficacy and Safety Evaluation of Mitapivat in Patients with Sickle Cell Disease: A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Multicenter Study
Data & Insights
Has run more than one trial at 37 of 59 partner sites.
Specializations
Haematologic malignancies
Rosario Di Maggio is involved in clinical research across a broad spectrum of lymphoid neoplasms and myeloid disorders, with particular attention to diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. The trial portfolio also includes Hodgkin lymphoma, peripheral T-cell lymphoma, marginal zone lymphoma, and multiple myeloma.
- Non-Hodgkin lymphoma
- Acute leukemia
- Multiple myeloma
- Chronic lymphocytic leukemia
The research activity reflects a strong therapeutic focus on targeted treatment strategies, immunotherapy, and transplant-associated care within specialised haematology practice.
Inflammatory bowel disease
Another major area of involvement is gastrointestinal inflammation, especially Crohn’s disease and ulcerative colitis. The investigator is linked to trials evaluating therapies for moderately to severely active inflammatory bowel disease, including patients with persistent disease activity and those requiring advanced disease control.
- Crohn’s disease
- Ulcerative colitis
- Endoscopic response
- Clinical remission
This area also extends to eosinophilic gastritis and related eosinophilic gastrointestinal disorders, broadening the therapeutic scope in immune-mediated digestive disease.
Hereditary angioedema and complement-mediated disease
Rosario Di Maggio is actively engaged in studies focused on hereditary angioedema, including both acute attack treatment and long-term prophylaxis. The research also includes patients with C1-inhibitor deficiency and recurrent angioedema syndromes requiring specialised preventive and on-demand management.
- Hereditary angioedema
- Acute angioedema attacks
- Prophylactic treatment
- C1-inhibitor deficiency
The therapeutic interest in this field centres on improving symptom control and reducing attack burden in rare complement-mediated disorders.
Myeloproliferative and marrow failure disorders
His clinical trial portfolio includes myelofibrosis, post-essential thrombocythaemia myelofibrosis, post-polycythaemia vera myelofibrosis, thrombocytopenic complications, and transplant-associated thrombotic microangiopathy. The research also covers sickle cell disease and beta-thalassemia, including complications such as iron overload and vaso-occlusive events.
- Myelofibrosis
- Transplant-associated thrombotic microangiopathy
- Sickle cell disease
- Beta-thalassemia
This research area highlights a therapeutic emphasis on rare blood disorders and complications linked to haematopoietic stem cell transplantation.
Solid tumours, vascular disease, and immune-mediated complications
Rosario Di Maggio is also involved in studies spanning lung cancer, biliary tract cancer, metastatic colorectal cancer, and coronary and cerebrovascular disease. Additional interest extends to stroke prevention, acute myocardial infarction, and graft-versus-host disease, including chronic graft-versus-host disease and treatment-resistant forms.
- Non-small cell lung cancer
- Biliary tract cancer
- Stroke prevention
- Chronic graft-versus-host disease
The portfolio reflects a clinical interest in oncology, vascular protection, and immune dysregulation across complex adult disease settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.